The firm will partner with startup GeneproDx on thyroid cancer diagnostic development, while a separate agreement with Endpoint Health will entail CDx development for critical illness.
Inflammatix said that if its test obtains Emergency Use Authorization next year, clinicians will be able to better gauge the severity of a COVID-19 patient's infection.
The companies are positioning the test, called SeptiCyte Rapid, for use in triaging COVID-19 patients who could be at greater risk for progressing to sepsis.
Sepset said its early test for sepsis, a condition that requires rapid diagnosis and treatment, would give clinicians valuable time to identify treatment strategies.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
